当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Reza Rastmanesh, Afrooz Javidi, Fourough A Taleban, Masood Kimaigar and Yadollah Mehrabi
Objective: We examined the ability of dietary fish oil to suppress markers of inflammation and consequent effect(s) on serum fasting glycemia, lipids, and blood pressure in patients with T2DM. Design: Correlations between serum fasting interleukin-6, Interleukin-1β (IL-1β), TNF-α (TNF-α), C-reactive Protein (CRP), and sialic acid, with indices of glycemia, insulin, and lipids were determined in 26 patients with T2DM at baseline, 4 weeks and 8 weeks after supplementation with fish oil (3 g/d) to analyse possible correlations between markers of inflammation and indices of glycemia. Results: There were no significant correlations between markers of inflammation with indices of glycemia at baseline, 4 weeks and 8 weeks after fish oils supplementation. Serum CRP concentrations were negatively correlated with fasting serum LDL, and with Cholesterol (r=-0.424, P<0.04; r=- 0.447, P<0.03, respectively). Fasting IL-1 β concentrations were positively correlated with fasting LDL, and with cholesterol at week 4 (r=0.482, P<0.02; r=0.469, P<0.02, respectively). There were no significant correlations between serum lipids with markers of inflammation at the end of intervention. There were no significant changes in serum fasting insulin, and glucose concentrations at the end of the intervention. Conclusions: A moderate dose of fish oil did not lead to deleterious effects on glycemic control in patients with T2DM, with preserved triacyglycerol-lowering capacities.